"Androstenes" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Unsaturated derivatives of the steroid androstane containing at least one double bond at any site in any of the rings.
Below are MeSH descriptors whose meaning is more general than "Androstenes".
Below are MeSH descriptors whose meaning is more specific than "Androstenes".
This graph shows the total number of publications written about "Androstenes" by people in Harvard Catalyst Profiles by year, and whether "Androstenes" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 1 | 0 | 1 |
| 2001 | 0 | 1 | 1 |
| 2003 | 1 | 2 | 3 |
| 2006 | 1 | 0 | 1 |
| 2007 | 2 | 0 | 2 |
| 2008 | 4 | 0 | 4 |
| 2009 | 3 | 1 | 4 |
| 2010 | 0 | 2 | 2 |
| 2011 | 0 | 4 | 4 |
| 2012 | 0 | 1 | 1 |
| 2013 | 1 | 3 | 4 |
| 2014 | 4 | 4 | 8 |
| 2015 | 3 | 1 | 4 |
| 2016 | 4 | 1 | 5 |
| 2017 | 2 | 5 | 7 |
| 2018 | 4 | 5 | 9 |
| 2019 | 4 | 3 | 7 |
| 2020 | 2 | 2 | 4 |
| 2021 | 3 | 4 | 7 |
| 2022 | 0 | 2 | 2 |
Below are the most recent publications written about "Androstenes" by people in Profiles.
-
Cardiovascular and Metabolic Diagnoses Associated With Novel Hormonal Agents for Prostate Cancer in Nontrial Populations. J Natl Cancer Inst. 2022 08 08; 114(8):1057-1058.
-
A phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancer. Future Oncol. 2022 Mar; 18(10):1185-1198.
-
Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial. J Clin Oncol. 2022 03 10; 40(8):825-836.
-
Circulating and Intratumoral Adrenal Androgens Correlate with Response to Abiraterone in Men with Castration-Resistant Prostate Cancer. Clin Cancer Res. 2021 11 01; 27(21):6001-6011.
-
Beyond Frontline Therapy with Abiraterone and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer: A Real-World US Study. Clin Genitourin Cancer. 2021 12; 19(6):480-490.
-
Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2021 07 10; 398(10295):131-142.
-
Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer. J Clin Oncol. 2021 09 10; 39(26):2926-2937.
-
An Unusual Case of Right Flank Pain. Am J Kidney Dis. 2021 07; 78(1):A12-A14.
-
An up-to-date evaluation of abiraterone for the treatment of prostate cancer. Expert Opin Pharmacother. 2021 Jul; 22(10):1227-1234.
-
Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide. Clin Cancer Res. 2021 07 15; 27(14):4077-4088.